Scalper1 News
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to 46.86 in afternoon trading in the stock market today. The stock had been declining through March before bouncing off its 50-day line late last week. Under the deal, Merck KGaA — a separate company Scalper1 News
Scalper1 News